Eli Lilly (LLY) is trading at $1,405.13, slightly below its 20-day average and down 1.66% over the last 24 hours, even as the stock remains near the top of its range and Wall Street continues to ra...
Eli Lilly (LLY) is still priced like a quality-growth leader, but the tape is not clean in the very near term. The stock is at $1,405.13, down 1.66% on the day, with a 24-hour range of $1,432.27 to $1,400.03. That puts shares just below the 20-day average at $1,411.31 and the 7-day average at $1,427.15, while still well above the 50-day average at $1,299.47.
The bigger fundamental story remains intact. On October 29, Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, and raised its full-year 2026 revenue guidance midpoint by $5.5 billion to a range of $91.0 billion to $92.0 billion. The company also lifted underlying non-GAAP EPS guidance at the midpoint. That is the core reason the stock keeps attracting higher price targets.
The latest broker notes point in the same direction, even if they do not remove short-term volatility. Barclays raised its target to $1,550 from $1,400 and kept an overweight rating. RBC Capital reiterated Outperform and set a $1,600 target, while Jefferies lifted its target to $1,700 from $1,610 and maintained a Buy rating.
Those targets matter because they frame the market’s willingness to pay up for Lilly’s pipeline and execution. RBC also highlighted the company’s Innovation Day on December 7 as a strategically important event for showing growth beyond obesity, which gives investors a known date to watch.
Source link







